Barinthus Biotherapeutics (BRNS) Long-Term Deferred Tax (2021)

Barinthus Biotherapeutics (BRNS) reported Long-Term Deferred Tax of $60000.0 for Q3 2021, up 87.5% quarter-over-quarter from $32000.0 in Q2 2021.

Barinthus Biotherapeutics (BRNS) Long-Term Deferred Tax (2021) Analysis & Trends

Barinthus Biotherapeutics has reported Long-Term Deferred Tax for 1 years, with the latest figure at $60000.0 in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn
9	Abivax	95.45 Bn	95.45 Bn	-
10	Barinthus Biotherapeutics	27.57 Mn	-39.54 Mn	-

Download Data